Time after dosing (hours) | Enrolment (SD) | 4 months (SD) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
 | N | Human immunodeficiency virus-infected | N | Human immunodeficiency virus-uninfected | P value | N | Human immunodeficiency virus-infected | N | HIV-uninfected | P value |
0.75 | 21 | 2.35(2.54) | 32 | 4.02(5.10) | 0.12 | 20 | 3.11(3.45) | 33 | 3.84(3.72) | 0.47 |
1.5 | 21 | 4.26(1.96) | 33 | 5.63(4.07) | 0.10 | 21 | 4.28(2.66) | 33 | 5.31(3.01) | 0.19 |
2.01 | 21 | 3.90(1.67) | 33 | 5.07(3.59) | 0.11 | 21 | 4.00(2.04) | 32 | 4.61(2.43) | 0.33 |
3.0 | 20 | 3.01(1.96) | 33 | 3.93(3.50) | 0.22 | 21 | 3.43(2.83) | 32 | 3.58(2.42) | 0.84 |
4.0 | 21 | 2.22(1.67) | 32 | 3.17(4.54) | 0.29 | 20 | 2.60(1.74) | 32 | 2.41(1.94) | 0.72 |
6.0 | 16 | 1.12(1.41) | 28 | 1.95(4.45) | 0.37 | 17 | 1.09(0.88) | 30 | 0.88(0.96) | 0.47 |
C max (μg/ml) | 21 | 4.91(2.03) | 33 | 6.92(5.88) | 0.08 | 21 | 5.67(3.30) | 33 | 6.26(3.41) | 0.53 |
T max (hour) | 21 | 1.80(0.87) | 33 | 1.67(0.93) | 0.62 | 21 | 2.17(1.30) | 33 | 1.71(0.88) | 0.17 |
AUC0–6 (μg/hour/ml) | 21 | 14.88(7.43) | 32 | 18.07(12.52) | 0.25 | 21 | 16.52(8.84) | 33 | 17.94(10.36) | 0.59 |